For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …

Anemia is a common feature and complication of chronic kidney disease (CKD).
Erythropoiesis-stimulating agents (ESAs) and recombinant human erythropoietin have been …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Introduction: In the last decade, concerns have been raised around the use of erythropoiesis-
stimulating agents (ESAs) and intravenous iron in chronic kidney disease (CKD) patients …

What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …

HIF-PHIs have several advantages including oral administration, physiological EPO
secretion, and improved iron utilization. Undoubtedly, HIF-PHIs will pave the new way in the …

Background: Anemia is a common complication of chronic kidney disease. The hypoxia-
inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the …

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-
class new generation drugs for renal anemia. This extensive meta-analysis of randomized …